2.84 USD
▼-0.07-2.41%
盘后 2.94 0.00%
2026-11-20
市值
$253.15M
市盈率
—
EPS
-1.49
股息率
—
52 周区间
2.44 – 5.15
成交量
538.14K
Beta
0.75
目标价
11.64
52W 低 2.4452W 高 5.15
价格走势
公司简介
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.